Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Barrientos JC"'
Autor:
Shah A, Barrientos JC
Publikováno v:
OncoTargets and Therapy, Vol Volume 14, Pp 2109-2119 (2021)
Ankit Shah,1 Jacqueline C Barrientos2 1Division of Hematology-Oncology, Department of Medicine at Rutgers New Jersey Medical School, Newark, NJ, USA; 2CLL Research and Treatment Center, Division of Hematology-Oncology, Department of Medicine at Zucke
Externí odkaz:
https://doaj.org/article/861f9b83f8a34d27b5e483f246027a58
Autor:
Barrientos JC
Publikováno v:
OncoTargets and Therapy, Vol 2016, Iss Issue 1, Pp 2945-2953 (2016)
Jacqueline C Barrientos CLL Research and Treatment Program, Division of Hematology/Oncology, Department of Medicine, Hofstra Northwell School of Medicine, Hofstra University, Lake Success, NY, USA Abstract: Idelalisib is a first-in-class, oral, selec
Externí odkaz:
https://doaj.org/article/533a17419d1d4112bc69382b8199e463
Autor:
Sharman, J, Barrientos, JC, Ghosh, N, Brander, D, Gutierrez, M, Wu, L, Panjabi, S, Upasani, S, Jermain, M, Naganuma, M, Mato, A
Publikováno v:
In Value in Health July 2022 25(7) Supplement:S564-S564
Autor:
Brown, JR, Hillmen, P, O'Brien, S, Barrientos, JC, Reddy, NM, Coutre, SE, Tam, CS, Mulligan, SP, Jaeger, U, Barr, PM, Furman, RR, Kipps, TJ, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, JM, Munir, T, Burger, JA, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, DF, Byrd, JC
In the phase 3 RESONATE(TM) study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::46e70b6f834dc8bd6475425e1a8c1a59
https://eprints.whiterose.ac.uk/118291/10/leu2017175.pdf
https://eprints.whiterose.ac.uk/118291/10/leu2017175.pdf
Autor:
Byrd, Jc, Brown, Jr, O'Brien, S, Barrientos, Jc, Kay, Ne, Reddy, Nm, Coutre, S, Tam, Cs, Mulligan, Sp, Jaeger, U, Devereux, S, Barr, Pm, Furman, Rr, Kipps, Tj, Cymbalista, F, Pocock, C, Thornton, P, Caligaris Cappio, F, Robak, T, Delgado, J, Schuster, Sj, Montillo, M, Schuh, A, de Vos, S, Gill, D, Bloor, A, Dearden, C, Moreno, C, Jones, Jj, Chu, Ad, Fardis, M, Mcgreivy, J, Clow, F, James, Df, Hillmen, P, Semenzato, GIANPIETRO CARLO
Publikováno v:
The New England journal of medicine, vol 371, iss 3
NEW ENGLAND JOURNAL OF MEDICINE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
NEW ENGLAND JOURNAL OF MEDICINE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80208a00a4b6a2c13b3b1c7cdaabb239
http://hdl.handle.net/11577/3156149
http://hdl.handle.net/11577/3156149
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Susan O'Brien, Paolo Ghia, William G. Wierda, S Devereux, Jennifer A. Woyach, Raquel Izumi, Jennifer R. Brown, Wayne Rothbaum, Ahmed Hamdy, Jesse McGreivy, Richard R. Furman, Jacqueline C. Barrientos, Amy J. Johnson, John M. Pagel, Thomas G. Diacovo, Xiaolin Wang, Jorge M. Chaves, Deborah M. Stephens, Maria Fardis, Allard Kaptein, Brian J. Lannutti, Dave Johnson, Bonnie K. Harrington, John C. Byrd, Jeffrey A. Jones, Farrukh T. Awan, Todd Covey, Jane Huang, Peter Hillmen, Anna Schuh
Publikováno v:
The New England journal of medicine, vol 374, iss 4
Background Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase ta
Autor:
Thomas J. Ervin, Ian W. Flinn, Andrew R. Pettitt, Nicole Lamanna, Richard R. Furman, Dave Johnson, John M. Pagel, Jeff P. Sharman, Paula Cramer, Stephan Stilgenbauer, Bruce D. Cheson, Maria Aiello, Bertrand Coiffier, Jacqueline C. Barrientos, Paolo Ghia, Thomas J. Kipps, Steven Coutre, Andrew D. Zelenetz, Roger Dansey, Peter Hillmen, Michael Hallek, Susan O'Brien, Shuo Ma, Thomas Jahn, Herbert Eradat, Langdon L. Miller, Daniel Li
Publikováno v:
The New England journal of medicine, vol 370, iss 11
BackgroundPatients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::436691d933194bc1ba11ec2adf5164a2
https://europepmc.org/articles/PMC4161365/
https://europepmc.org/articles/PMC4161365/
Autor:
Ghosh N; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. Electronic address: nilanjan.ghosh@atriumhealth.org., Sharman JP; Willamette Valley Cancer Institute & Research Center/US Oncology Research, Eugene, OR, USA., Gutierrez M; Lymphoma Research Foundation, New York City, NY, USA., Khan W; Janssen, Horsham, PA, USA., Qureshi ZP; Janssen, Horsham, PA, USA., Raz A; AbbVie, North Chicago, IL, USA., Girardi V; AbbVie, North Chicago, IL, USA., Krigsfeld GS; AbbVie, North Chicago, IL, USA., Barrientos JC; Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA.
Publikováno v:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Sep; Vol. 24 (9), pp. e301-e313. Date of Electronic Publication: 2024 May 13.